phosphorylated (p-)jak2 antibody  (Cell Signaling Technology Inc)

Journal: Molecular Medicine Reports

Article Title: Naringin ameliorates intestinal injury in ulcerative colitis model mice by modulating the JAK2/STAT3 signaling pathway

doi: 10.3892/mmr.2026.13805

Figure Lengend Snippet: Naringin inhibits JAK2/STAT3 signaling and restores tight junction proteins in dextran sulfate sodium-induced colitis. (A) Representative western blotting images of p-JAK2, JAK2, p-STAT3, STAT3, IL-6, occludin, ZO-1 and β-actin expression in colon tissues. Densitometric semi-quantification of the relative protein expression levels of (B) p-JAK2/β-actin, (C) JAK2/β-actin, (D) p-JAK2/JAK2, (E) p-STAT3/β-actin, (F) STAT3/β-actin, (G) p-STAT3/STAT3, (H) IL-6/β-actin, (I) occludin/β-actin and (J) ZO-1/β-actin. Data are presented as mean ± SEM. n=3. *P<0.05 and **P<0.01 vs. control group; # P<0.05 and ## P<0.01 vs. normal group. One-way ANOVA followed by Tukey's post-hoc test was applied. N, normal group; C, control group; Nar, naringin group; Mes, mesalazine group; p-, phosphorylated; JAK2, Janus kinase 2; STAT3, signal transducer and activator of transcription 3; IL-6, ZO-1, zona occludens-1.

Article Snippet: The membranes were blocked with 5% non-fat dry milk in Tris-buffered saline containing 0.1% Tween-20 (TBST) for 2 h at room temperature, then incubated at 4°C overnight with primary antibodies against IL-6 (1:1,000; cat. no. Bs-0782R; BIOSS), phosphorylated (p-)JAK2 (1:1,000; cat. no. bs-2485R; BIOSS), JAK2 (1:1,000; cat. no. bs-0908R; BIOSS), p-STAT3 (1:1,000; cat. no. bs-1658R; BIOSS), STAT3 (1:1,000; cat. no. bs-55208R; BIOSS), occludin (1:1,000; cat. no. A2601; ABclonal Biotech Co., Ltd.), zona occludens-1 (ZO-1; 1:1,000; cat. no. A0659; ABclonal Biotech Co., Ltd.) and β-actin (1:1,000; cat. no. ab8227; Abcam).

Techniques: Western Blot, Expressing, Control

Journal: Molecular Medicine Reports

Article Title: Naringin ameliorates intestinal injury in ulcerative colitis model mice by modulating the JAK2/STAT3 signaling pathway

doi: 10.3892/mmr.2026.13805

Figure Lengend Snippet: Naringin suppresses JAK2/STAT3 activation in IL-6-stimulated Caco-2 cells with STAT3 silencing. (A) Western blot analysis of p-JAK2, JAK2, p-STAT3, STAT3, occludin and ZO-1 in Caco-2 cells under indicated treatments. (B) Validation of STAT3 knockdown efficiency: Relative STAT3 expression in cells transfected with siSTAT3 vs. siNC. ## P<0.01 vs. siNC. Densitometric semi-quantification of relative protein expression levels of (C) p-JAK2/β-actin, (D) JAK2/β-actin, (E) p-JAK2/JAK2, (F) p-STAT3/β-actin, (G) STAT3/β-actin, (H) p-STAT3/ STAT3, (I) occludin/β-actin, (J) ZO-1/β-actin. Data are presented as mean ± SEM. n=3. *P<0.05 and **P<0.01 vs. IL-6 group; ## P<0.01 vs. normal group; Δ P<0.05 and ΔΔ P<0.01 IL-6 + Nar group vs. IL-6 + Nar + siSTAT3 group. One-way ANOVA followed by Tukey's post-hoc test was applied. N, normal group; Nar, naringin group; Mes, mesalazine group; p-, phosphorylated; JAK2, Janus kinase 2; STAT3, signal transducer and activator of transcription 3; ZO-1, zona occludens-1; si, small interfering RNA; NC, negative control.

Article Snippet: The membranes were blocked with 5% non-fat dry milk in Tris-buffered saline containing 0.1% Tween-20 (TBST) for 2 h at room temperature, then incubated at 4°C overnight with primary antibodies against IL-6 (1:1,000; cat. no. Bs-0782R; BIOSS), phosphorylated (p-)JAK2 (1:1,000; cat. no. bs-2485R; BIOSS), JAK2 (1:1,000; cat. no. bs-0908R; BIOSS), p-STAT3 (1:1,000; cat. no. bs-1658R; BIOSS), STAT3 (1:1,000; cat. no. bs-55208R; BIOSS), occludin (1:1,000; cat. no. A2601; ABclonal Biotech Co., Ltd.), zona occludens-1 (ZO-1; 1:1,000; cat. no. A0659; ABclonal Biotech Co., Ltd.) and β-actin (1:1,000; cat. no. ab8227; Abcam).

Techniques: Activation Assay, Western Blot, Biomarker Discovery, Knockdown, Expressing, Transfection, Small Interfering RNA, Negative Control

Journal: Oncology Letters

Article Title: Silymarin induces multiple myeloma cell apoptosis by inhibiting the JAK2/STAT3 signaling pathway

doi: 10.3892/ol.2025.15172

Figure Lengend Snippet: Silymarin inhibits the JAK2/STAT3 signaling pathway in multiple myeloma cells. mRNA expression levels of (A) Bcl-2 and (B) Bcl-xL in the RPMI 8226 cell line (n=3). mRNA expression levels of (C) Bcl-2 and (D) Bcl-xL in the H929 cell line (n=3). Immunofluorescence images of (E) JAK2 and (F) pJAK2. (G) Semi-quantification of levels of pJAK2 in the RPMI 8226 cell line (n=4). Immunofluorescence images of (H) STAT3 and (I) pSTAT3. Semi-quantification of (J) levels of pSTAT3 and (K) nuclear localization of pSTAT3 in the RPMI 8226 cell line (n=4). *P<0.05; **P<0.01; ***P<0.001. Error bars indicate standard deviation. p, phosphorylated; AU, arbitrary units.

Article Snippet: Subsequently, 5% bovine serum albumin (BSA; cat. no. A9418; MilliporeSigma) was applied to block nonspecific binding for 15 min. Primary antibodies targeting JAK2 (1:500; cat. no. PA5-11267; Thermo Fisher Scientific, Inc.), phosphorylated-JAK2 (1:500; cat. no. PA5-99341; Thermo Fisher Scientific, Inc.), STAT3 (1:100; cat. no. MA1-13042; Thermo Fisher Scientific, Inc.) and phosphorylated-STAT3 (1:100; cat. no. PA5-17876; Thermo Fisher Scientific, Inc.) were added to the cells and incubated overnight at 4°C.

Techniques: Expressing, Immunofluorescence, Standard Deviation

Journal: Oncology Letters

Article Title: Silymarin induces multiple myeloma cell apoptosis by inhibiting the JAK2/STAT3 signaling pathway

doi: 10.3892/ol.2025.15172

Figure Lengend Snippet: Interaction mode between silymarin and JAK2/STAT3. (A) Docking diagram of silymarin and JAK2 protein. (B) Docking diagram of silymarin and STAT3 protein. In addition, the planar structure of silymarin can be seen in the 2D image.

Article Snippet: Subsequently, 5% bovine serum albumin (BSA; cat. no. A9418; MilliporeSigma) was applied to block nonspecific binding for 15 min. Primary antibodies targeting JAK2 (1:500; cat. no. PA5-11267; Thermo Fisher Scientific, Inc.), phosphorylated-JAK2 (1:500; cat. no. PA5-99341; Thermo Fisher Scientific, Inc.), STAT3 (1:100; cat. no. MA1-13042; Thermo Fisher Scientific, Inc.) and phosphorylated-STAT3 (1:100; cat. no. PA5-17876; Thermo Fisher Scientific, Inc.) were added to the cells and incubated overnight at 4°C.

Techniques: